Updated just now · Live
Stock analysis, price data, and AI-powered insights for Xilio Therapeutics Inc (XLO).
Xilio Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for XLO.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). XLO Stock Intelligence Report. [stoxpulse.com/stocks/xlo]
Disclaimer: The information on this page about Xilio Therapeutics Inc (XLO) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Xilio Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Xilio's XTX601 Shows Tumor-Selective Activation An...
4d ago
Xilio Therapeutics Announces New Preclinical Data ...
4d ago
StoxPulse AI results for XLO: Pulse Score 53/100. Primary sentiment trends from 3 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$49.7M
P/E Ratio
—
EPS
$-0.11
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors